pharmaphorum

NOVEMBER 11, 2022

Pick the brains of 140+ senior level drug developers across industry and academia at the physical return of the only meeting dedicated to overcoming challenges in biomarker understanding, disease selection and clinical translation in inflammasome-centered drug development.

Medical Schools 52

Medical Schools Immunity Immunization Hospitals 52

pharmaphorum

DECEMBER 4, 2020

With momentum building for antigen specific immunotherapies, ASIT 2021 will be the only antigen-specific summit offering thought-leading content to drive the field towards a more precise and ethical antigen-specific approach to drug development. This is the industry’s definitive antigen specific drug development forum.

Immunity 52

Immunity Immunization Medical Schools Drug Development 52

Express Pharma

DECEMBER 7, 2023

Because a critical part of the effective use of AI depends on having the relevant data for the model to get trained, Ceremorphic Life Sciences has developed unique technology to create the relevant data for AI foundation model creation using BioCompDiscoverX. This is key to the platform efficiency.

Medical Schools 105

Medical Schools Vaccines Drug Development 105

STAT

MARCH 6, 2023

That business is one of three that help to design and manufacture vaccines for JLF, along with Washington University’s medical school. Before he died in 2020, Aldrich concluded that other patients might benefit from such vaccines and started the firm now called NoRD Bio.

Vaccines 246

Vaccines Bioethics Immunity Immunization 246

pharmaphorum

NOVEMBER 22, 2021

The inaugural Next Generation Kinase Inhibitors Summit is the only industry-focused meeting dedicated to applying novel kinase biology to drug development and innovating existing programs to produce the next wave of kinase inhibitor drugs that are able to show efficacious and durable clinical response in oncology and beyond.

Drug Development 52

Drug Development Medical Schools 52

European Pharmaceutical Review

AUGUST 9, 2024

Potential of nipocalimab for HDFN “Nipocalimab is the only drug in development with the potential to treat a variety of alloimmune diseases that affect the foetus such as foetal/neonatal alloimmune thrombocytopenia and immune-mediated congenital heart block,” lead study investigator Dr Kenneth Moise Jr. ,

Medical Schools 52

Medical Schools Immunity Immunization Drug Development 52

Pharmaceutical Technology

JUNE 12, 2023

The evidence for clinical benefit was “very clear”, said Dr. Merit Cudkowicz, Julieanne Dorn professor of neurology at Harvard University’s Medical School. Leqembi is the second drug developed by Biogen and Eisai for the treatment of Alzheimer’s disease.

Medical Schools 52

Medical Schools Labelling Drug Development 52

European Pharmaceutical Review

SEPTEMBER 2, 2022

She also has been conducting fundamental research as an academic in several universities, with her last academic position held at Harvard Medical School. US Food and Drug Administration. She holds a MSc in Public Health and a PhD in Biophysics and Molecular Biology. About the author. References. Risk management plan [Internet].

Adverse Reactions 96

Adverse Reactions Documentation Medical Schools Packaging 96

European Pharmaceutical Review

MAY 8, 2024

This will help address a variety of indications with high unmet medical needs, such as autoimmune diseases, cancer, and neurological disorders. Before that, he held positions as a principal investigator at the University of Tuebingen, Germany, and a prior postdoc position at Harvard Medical School in Boston. Johannes B.

Medical Schools 98

Medical Schools Drug Development 98

European Pharmaceutical Review

DECEMBER 11, 2023

1 However, research related to RNA therapeutics has also consistently reinforced limitations that drug developers are steadfastly working to address – primarily that delivery of most RNA therapies has thus far been limited to the liver and unable to target other tissues in the body. References 1. 2019;380:1.

Medical Schools 98

Medical Schools Drug Development 98

European Pharmaceutical Review

DECEMBER 28, 2023

About the interviewee Dr Andreas Harstrick joined Affimed as CMO in 2020, bringing with him more than 30 years of experience and expertise in cancer drug development, clinical trial research, and regulatory approvals. at the Hannover Medical School, Germany, and spent his career as a practicing oncologist.

Immunity 84

Immunity Immunization Chemotherapy Medical Schools 84

European Pharmaceutical Review

JULY 25, 2024

Moreover, we are witnessing a rising trend of drug developers focusing on diseases with high unmet needs, especially those that are terminal or are aggressively progressive, particularly where other treatment options are either inadequate or non-existent.

Medical Schools 52

Medical Schools Drug Development 52

Pharmaceutical Technology

APRIL 24, 2023

In an email to this news service, João Conde, PhD, professor at NOVA Medical School, Universidade NOVA de Lisboa, said advances like the mRNA vaccines serve as a testament to the breakthroughs made by science over decades of research at the junction of genetics and nanomedicine.

Vaccines 59

Vaccines Immunity Immunization Medical Schools 59

Pharmaceutical Technology

NOVEMBER 28, 2022

The country has one of the largest life science clusters in Europe and is also home to five of the top medical schools in the UK. To learn more about the development and partnership opportunities for businesses within Scotland’s health sector, download the document on this page. Free Whitepaper.

Hospitals 52

Hospitals Packaging Medical Schools Documentation 52